Page last updated: 2024-12-11

4-amylcinnamoylanthranilic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-amylcinnamoylanthranilic acid: phospholipase A2 inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-(p-amylcinnamoyl)anthranilic acid : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 4-pentylcinnamoyl group. It is a transient receptor potential (TRP) channel blocker and phospholipase A2 (PLA2) inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5353376
CHEMBL ID173443
CHEBI ID139349
CHEBI ID114200
MeSH IDM0227841

Synonyms (52)

Synonym
2-((1-oxo-3-(4-pentylphenyl)-2-propenyl)amino)benzoic acid
benzoic acid, 2-((1-oxo-3-(4-pentylphenyl)-2-propenyl)amino)-
4-acaa
BRD-K77817104-001-01-3
gtpl2443
ACA ,
n-(p-amylcinnamoyl)anthranilic acid
HSCI1_000235
CHEBI:139349
p-amylcinnamoylanthranilic acid
2-{[(2e)-3-(4-pentylphenyl)prop-2-enoyl]amino}benzoic acid
CHEBI:114200
4-amylcinnamoylanthranilic acid
110683-10-8
2-[[(e)-3-(4-pentylphenyl)prop-2-enoyl]amino]benzoic acid
CHEMBL173443 ,
2-[3-(4-pentylphenyl)prop-2-enoylamino]benzoic acid
benzoic acid, 2-[[(2e)-1-oxo-3-(4-pentylphenyl)-2-propenyl]amino]-
99196-74-4
n-(p-amylcinnamoyl) anthranilic acid (aca)
GAMRBCZMOOMBSQ-CCEZHUSRSA-N
trans-4-n-pentylcinnamic acid-n-(2-carboxy-phenyl)-amide
J-002463
n-(p-amylcinnamoyl)anthranilic acid, >=98% (hplc)
2-(3-(4-pentylphenyl)acrylamido)benzoic acid
AKOS027446626
n-(p-amylcinnamoyl) anthranilic acid
(e)-2-(3-(4-pentylphenyl)acrylamido)benzoic acid
aca - cas 110683-10-8
n-(4-pentylcinnamoyl)anthranilic acid
BS-14363
bdbm50227083
Q6951332
CS-0067650
HY-118628
n-(p-amylcinnamoyl)-anthranilic-acid
N17081
2-[[1-oxo-3-(4-pentylphenyl)-2-propen-1-yl]amino]benzoic acid
benzoic acid, 2-[[1-oxo-3-(4-pentylphenyl)-2-propen-1-yl]amino]-
2-(3-(4-pentylphenyl)acrylamido)benzoicacid
benzoic acid, 2-(((2e)-1-oxo-3-(4-pentylphenyl)-2-propenyl)amino)-
benzoic acid, 2-((1-oxo-3-(4-pentylphenyl)-2-propenyl)amino)-, (e)-
benzoic acid, 2-(((2e)-1-oxo-3-(4-pentylphenyl)-2-propen-1-yl)amino)-
unii-lcj9m6aj5f
2-((1-oxo-3-(4-pentylphenyl)-2-propen-1-yl)amino)benzoic acid
benzoic acid, 2-((1-oxo-3-(4-pentylphenyl)-2-propen-1-yl)amino)-
2-(((2e)-1-oxo-3-(4-pentylphenyl)-2-propen-1-yl)amino)benzoic acid
lcj9m6aj5f ,
bml264
DTXSID401166445
2-[[(2e)-1-oxo-3-(4-pentylphenyl)-2-propen-1-yl]amino]benzoic acid
Z2315579457

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The dose-response study of AA and IDM demonstrated that the concentration of intracellular AA accumulated by IDM is less than 100 nm."( Enhancement of Ca2+-regulated exocytosis by indomethacin in guinea-pig antral mucous cells: arachidonic acid accumulation.
Fujiwara, S; Kato, M; Katsu, K; Nakahari, T; Nakanishi, Y; Shimamoto, C, 2006
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
EC 3.1.1.4 (phospholipase A2) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4).
TRP channel blockerAn agent that inhibits the passage of cations through the transient receptor potential (TRP) channels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
amidobenzoic acid
cinnamamidesAn enamide which is cinnamamide or a derivative of cinnamamide obtained by replacement of one or more of its hydrogens.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily M member 2Homo sapiens (human)IC50 (µMol)1.93670.21001.89115.0000AID1065920; AID1359285; AID1359292; AID1359293; AID1503220; AID1775860
Phospholipase A2Homo sapiens (human)IC50 (µMol)22.00000.00300.91223.9000AID1775868
Transient receptor potential cation channel subfamily M member 8Homo sapiens (human)IC50 (µMol)3.90000.02001.27553.9000AID1359294; AID1775865
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)EC50 (µMol)28.09190.00033.166210.0000AID1549771
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (65)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature homeostasisTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
dendritic cell chemotaxisTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to heatTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to purine-containing compoundTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
regulation of actin cytoskeleton organizationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
response to hydroperoxideTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
sodium ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
release of sequestered calcium ion into cytosolTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
regulation of filopodium assemblyTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to calcium ionTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to purine-containing compoundTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
manganese ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cellular response to temperature stimulusTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
zinc ion transmembrane transportTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
dendritic cell differentiationTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion transmembrane import into cytosolTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
positive regulation of interleukin-8 productionPhospholipase A2Homo sapiens (human)
positive regulation of MAP kinase activityPhospholipase A2Homo sapiens (human)
innate immune response in mucosaPhospholipase A2Homo sapiens (human)
neutrophil mediated immunityPhospholipase A2Homo sapiens (human)
fatty acid biosynthetic processPhospholipase A2Homo sapiens (human)
actin filament organizationPhospholipase A2Homo sapiens (human)
signal transductionPhospholipase A2Homo sapiens (human)
positive regulation of cell population proliferationPhospholipase A2Homo sapiens (human)
positive regulation of calcium ion transport into cytosolPhospholipase A2Homo sapiens (human)
lipid catabolic processPhospholipase A2Homo sapiens (human)
leukotriene biosynthetic processPhospholipase A2Homo sapiens (human)
antibacterial humoral responsePhospholipase A2Homo sapiens (human)
neutrophil chemotaxisPhospholipase A2Homo sapiens (human)
activation of phospholipase A2 activityPhospholipase A2Homo sapiens (human)
cellular response to insulin stimulusPhospholipase A2Homo sapiens (human)
intracellular signal transductionPhospholipase A2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIPhospholipase A2Homo sapiens (human)
regulation of glucose importPhospholipase A2Homo sapiens (human)
phosphatidylcholine metabolic processPhospholipase A2Homo sapiens (human)
phosphatidylglycerol metabolic processPhospholipase A2Homo sapiens (human)
positive regulation of fibroblast proliferationPhospholipase A2Homo sapiens (human)
arachidonic acid secretionPhospholipase A2Homo sapiens (human)
positive regulation of protein secretionPhospholipase A2Homo sapiens (human)
positive regulation of immune responsePhospholipase A2Homo sapiens (human)
defense response to Gram-positive bacteriumPhospholipase A2Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityPhospholipase A2Homo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptidePhospholipase A2Homo sapiens (human)
positive regulation of podocyte apoptotic processPhospholipase A2Homo sapiens (human)
phospholipid metabolic processPhospholipase A2Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
positive regulation of cold-induced thermogenesisTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (19)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
hydrolase activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ADP-ribose diphosphatase activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
monoatomic cation channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
sodium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
manganese ion transmembrane transporter activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
calcium ion bindingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
mono-ADP-D-ribose bindingTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ligand-gated calcium channel activityTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
phospholipase A2 activityPhospholipase A2Homo sapiens (human)
signaling receptor bindingPhospholipase A2Homo sapiens (human)
calcium ion bindingPhospholipase A2Homo sapiens (human)
bile acid bindingPhospholipase A2Homo sapiens (human)
calcium-dependent phospholipase A2 activityPhospholipase A2Homo sapiens (human)
phospholipid bindingPhospholipase A2Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
ligand-gated calcium channel activityTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (16)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
lysosomeTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
lysosomal membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cytoplasmic vesicle membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
specific granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
cell projectionTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
perikaryonTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
tertiary granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
ficolin-1-rich granule membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 2Homo sapiens (human)
extracellular regionPhospholipase A2Homo sapiens (human)
extracellular spacePhospholipase A2Homo sapiens (human)
cell surfacePhospholipase A2Homo sapiens (human)
endoplasmic reticulum membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
membrane raftTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily M member 8Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1446807Inhibition of cysteinyl leukotriene receptor in guinea pig trachea strip assessed as inhibition of LTD4-induced trachea strip contraction preincubated for 2 mins followed by LTD4 induction2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
AID1775860Inhibition of human TRPM2 expressed in HEK293T cells assessed as blocked of ADPR-activated current by whole cell patch clamp electrophysiology2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1359288Inhibition of human TRPM2 expressed in HEK293 cells assessed as reduction in ADPR-induced channel currents at 3 uM treated extracellularly after 60 secs by whole cell patch clamp electrophysiology method relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.
AID1775865Inhibition of human TRPM8 expressed in HEK293T cells assessed as blocked of menthol-activated current by whole cell patch clamp electrophysiology relative to control2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1549816Agonist activity at human TRPA1 Phe944Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 10 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1549817Agonist activity at human TRPA1 Phe944Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 30 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1549812Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 30 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1359292Inhibition of human TRPM2 expressed in HEK293 cells assessed as reduction in H2O2-induced intracellular calcium flux after 30 mins by Fluo4-AM dye based fluorescence assay2018European journal of medicinal chemistry, May-25, Volume: 152Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.
AID1775868Inhibition of PLA2 (unknown origin) using soybean phosphatidylcholine as substrate preincubated for 30 mins followed incubated for 60 mins after substrate addition by microplate reader relative to control2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1775863Inhibition of human TRPM8 expressed in HEK293T cells assessed as blocked of menthol-activated current at 10 uM by whole cell patch clamp electrophysiology relative to control2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1775861Inhibition of human TRPM2 expressed in HEK293T cells assessed as suppression of H2O2-induced calcium flux at 30 uM measured after 30 mins by Fluo-3/AM assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID78302Inhibition of LTC4 induced smooth muscle contraction of guinea pig ileum1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships.
AID1549771Agonist activity at human TRPA1 expressed in HEK293 cells assessed as increase in calcium influx by Fluo-4-AM dye based fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID1503220Inhibition of human TRPM2 expressed in HEK293 cells assessed as reduction in ADPR-induced intracellular calcium flux at 0 mV holding potential by whole cell patch clamp electrophysiology method2017Journal of natural products, 10-27, Volume: 80, Issue:10
Scalaradial Is a Potent Inhibitor of Transient Receptor Potential Melastatin 2 (TRPM2) Ion Channels.
AID1775869Inhibition of PLA2 (unknown origin) using soybean phosphatidylcholine as substrate at 3 uM preincubated for 30 mins followed incubated for 60 mins after substrate addition by microplate reader relative to control2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1784466Inhibition of human TRPM2 expressed in HEK293T cells cotransfected with GFP assessed as suppression of H2O2-induced calcium flux at 30 uM pretreated for 30 mins followed by H2O2 stimulation by Fluo-3/AM assay2021European journal of medicinal chemistry, Dec-05, Volume: 225Design, synthesis and biological activities of benzo[d]imidazo[1,2-a]imidazole derivatives as TRPM2-specfic inhibitors.
AID1775910Inhibition of human TRPM2 expressed in HEK293T cells assessed as suppression of H2O2-induced calcium flux at 1 uM measured after 30 mins by Fluo-3/AM assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1065920Inhibition of human TRPM2 expressed in HEK293 cells assessed as inhibition of H2O2-induced intracellular calcium level by patch clamp technique2013Journal of medicinal chemistry, Dec-27, Volume: 56, Issue:24
Structure-activity relationship of adenosine 5'-diphosphoribose at the transient receptor potential melastatin 2 (TRPM2) channel: rational design of antagonists.
AID1359284Inhibition of human TRPM2 expressed in HEK293 cells assessed as reduction in ADPR-induced channel currents at 30 uM treated extracellularly after 60 secs by whole cell patch clamp electrophysiology method relative to control2018European journal of medicinal chemistry, May-25, Volume: 152Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.
AID1775862Cytotoxicity against human SH-SY5Y cells assessed as toxicity at 30 uM incubated for 24 hrs by CCK-8 assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1775864Inhibition of human TRPM8 expressed in HEK293T cells assessed as blocked of menthol-activated current at 3 uM by whole cell patch clamp electrophysiology relative to control2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1359293Inhibition of human TRPM2 expressed in HEK293 cells assessed as reduction in ADPR-induced channel currents by whole cell patch clamp electrophysiology method2018European journal of medicinal chemistry, May-25, Volume: 152Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.
AID1775867Inhibition of PLA2 (unknown origin) using soybean phosphatidylcholine as substrate at 10 uM preincubated for 30 mins followed incubated for 60 mins after substrate addition by microplate reader relative to control2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
The Discovery of Novel ACA Derivatives as Specific TRPM2 Inhibitors that Reduce Ischemic Injury Both In Vitro and In Vivo.
AID1359294Inhibition of human TRPM8 expressed in HEK293 cells assessed as reduction in H2O2-induced intracellular calcium flux after 30 mins by Fluo4-AM dye based fluorescence assay2018European journal of medicinal chemistry, May-25, Volume: 152Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.
AID1549813Agonist activity at human TRPA1 Phe909Ala mutant expressed in HEK293 cells assessed as Ca2+ influx at 10 uM by fluorescence assay2019European journal of medicinal chemistry, May-15, Volume: 170N-Cinnamoylanthranilates as human TRPA1 modulators: Structure-activity relationships and channel binding sites.
AID76829In vivo inhibition of LTD4-induced bronchoconstriction in anesthetized guinea pig.1988Journal of medicinal chemistry, Jan, Volume: 31, Issue:1
New potent antagonists of leukotrienes C4 and D4. 1. Synthesis and structure-activity relationships.
AID1359285Inhibition of human TRPM2 expressed in HEK293 cells assessed as reduction in ADPR-induced channel currents treated extracellularly after 60 secs by whole cell patch clamp electrophysiology method2018European journal of medicinal chemistry, May-25, Volume: 152Design, synthesis and biological activities of 2,3-dihydroquinazolin-4(1H)-one derivatives as TRPM2 inhibitors.
AID1346628Human TRPM2 (Transient Receptor Potential channels)2006British journal of pharmacology, Jun, Volume: 148, Issue:3
Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (33)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.03)18.7374
1990's5 (15.15)18.2507
2000's11 (33.33)29.6817
2010's12 (36.36)24.3611
2020's4 (12.12)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.72 (24.57)
Research Supply Index3.53 (2.92)
Research Growth Index5.25 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other31 (93.94%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]